Stock Movers: CVS, Duolingo, McDonald's (Podcast)

CVS plans to spin off its retail pharmacy business as CVS Pharmacy in the first half of 2028, separating it from Aetna and Caremark; shares fell as much as 15% after the announcement. Duolingo shares rose 35% despite a narrow earnings miss, as daily active users increased 29% year over year to 64.9 million and bookings rose 12% to $316 million. McDonald’s third-quarter US comparable sales declined 0.2%, less than analysts expected, as higher spending per visit partly offset lower traffic.

Analysis

CVS: The separation could make each business easier to value, but it does not itself create cash flow or resolve operating challenges. The key question is whether standalone CVS Pharmacy can support its cost base and compete effectively, while the remaining insurance/PBM businesses retain sufficient scale and manage shared-cost separation. That uncertainty—not just the 2028 date—can keep the equity-risk premium elevated. Walgreens Boots Alliance is a relevant retail-pharmacy read-through, but CVS’s proposed structure is not proof of a sector-wide strategic shift. Near term, expect execution and capital-allocation questions; over 6–18 months, watch for disclosed standalone financials, separation costs, and regulatory milestones. The downside thesis weakens if CVS provides credible, detailed segment economics and the shares stabilize without deterioration in operating guidance.

Duolingo: The market appears to be valuing engagement as an option on future monetization, not rewarding current bookings growth alone. A large reaction to user metrics raises the bar for converting activity into paid subscribers and revenue per user; failure to do so could unwind part of the move. Track bookings per active user, paid conversion, and guidance over the next quarter or two. The bull case is falsified by engagement deceleration or bookings failing to catch up; a narrow earnings miss alone is less informative.

McDonald’s: A smaller-than-feared sales decline is a relative positive, not evidence that US traffic has recovered. Higher spend per visit may cushion revenue while value-sensitive customers remain a risk. The durability of the replacement value program matters more than one quarter’s comparison. Monitor traffic and comparable sales against pricing and promotion intensity over coming quarters.

Key Decisions for Investors

• CVS: Avoid chasing the post-announcement selloff in either direction. Keep exposure neutral pending standalone segment economics, separation-cost estimates, and regulatory detail; reconsider a long only if guidance and the proposed cost structure support value creation. Reassess if operating guidance deteriorates or separation costs materially exceed expectations.
• DUOL: Do not add to the sharp gap-up solely on DAU growth. For existing longs, consider trimming or using a defined-risk collar; re-enter only if subsequent bookings and paid conversion validate engagement. A reversal in bookings momentum or user growth would challenge the rerating.
• MCD: Prefer a measured hold over a broad consumer-recovery trade. Watch US traffic and comparable sales alongside evidence that value offers sustain visits without relying on heavier discounting; renewed traffic weakness would invalidate the near-term stabilization case.